$AZN (AstraZeneca PLC)

$AZN {{ '2016-01-28T16:18:59+0000' | timeago}} • Webcast

$BMY, which competes with $AZN and $PFE, said it expects 2016 revenues to grow about 5% and a strong double-digit EPS growth. The company also said it expects strong performance in Opdivo, given the strong execution in the US and launches in more countries, as it secures additional approvals with associated pricing and reimbursement.

$PG {{ '2017-10-20T19:57:21+0000' | timeago}} • Webcast

$PG still expects majority of EPS growth for 2018 to be driven by operating and earnings growth. The 1Q18 was a little bit more challenging, due to run up of commodity cost and the impact of the natural disasters. The productivity savings will build as $PG grows through the fiscal year and will also began annualizing pricing reductions investment.

$PG {{ '2017-10-20T19:46:37+0000' | timeago}} • Webcast

$PG expects to grow China Baby Care sales this fiscal year and return Pampers to share growth which would mark a significant turnaround. $PG continues to build share in ecommerce in China. $PG grew ecommerce sales about 60% in 1Q18 and a market growing around 50% with 7 out of 10 categories holding growing online market share.

$PG {{ '2017-10-20T19:43:52+0000' | timeago}} • Webcast

For FY18, $PG planned to deliver another year of 90% or better free cash flow productivity. This includes capital expenditures of 5-5.5% of sales. $PG continues its strong track record of cash return to shareholders. $PG expects to pay nearly $7.5Bil in dividends and repurchase $4-7Bil of its shares in FY18.

$PG {{ '2017-10-20T19:38:31+0000' | timeago}} • Webcast

$PG's results for 1Q18 includes about a 30 basis point impacts from the earthquake in Mexico and hurricanes in Texas to Gulf Coast and Puerto Rico. They also include a 40 basis point impact from the combination of U.S. pricing investments and discontinued brands of product forms. $PG said all of these impacts will dissipate as the year progresses.

$PG {{ '2017-10-20T12:44:20+0000' | timeago}} • Infographic

$PG The Procter & Gamble Co. Earnings AlphaGraphic: Q1 2018 Highlights

$PG {{ '2017-10-20T11:47:55+0000' | timeago}} • Announcement

$PG maintained its core EPS growth expectation of 5-7% versus FY17 Core EPS of $3.92. This is despite over $100MM of incremental commodity cost headwinds resulting from the hurricanes that impacted the Gulf Coast in September. All-in GAAP EPS are expected to decrease 26-28% versus 2017 GAAP EPS of $5.59.

$PG {{ '2017-10-20T11:45:58+0000' | timeago}} • Announcement

$PG maintained its guidance for organic sales growth in the range of 2-3% for FY18. The company estimates all-in sales growth of about 3% for FY18, which includes a neutral to half-a-percentage-point benefit to sales growth from the combined impacts of foreign exchange, acquisitions and divestitures.

$PG {{ '2017-10-20T11:44:44+0000' | timeago}} • Announcement

$PG's gross margin for 1Q18 decreased 40 basis points. On a currency-neutral basis, core gross margin fell 10 points as 150 points of productivity savings were more than offset by 70 points of commodity cost rises, 50 points of unfavorable geographic and product mix and 40 points of product reinvestments and other impacts.

$PG {{ '2017-10-20T11:41:13+0000' | timeago}} • Announcement

$PG's Baby, Feminine and Family Care segment organic sales for 1Q18 declined 1% from the prior year. Baby Care organic sales decreased mid-single digits due in part to competitive activity in Europe and a decline in China Baby Care shipments due primarily to wholesaler inventory run-down ahead of new innovation shipments.

$PG {{ '2017-10-20T11:40:58+0000' | timeago}} • Announcement

$PG's Health Care segment organic sales for 1Q18 rose 1%. Oral Care organic sales increased low single digits behind product innovation on power toothbrushes and toothpaste and increased marketing support. Personal Health Care organic sales slid low single digits on lower volume.

$PG {{ '2017-10-20T11:40:39+0000' | timeago}} • Announcement

$PG's grooming segment organic sales for 1Q18 fell 6% on lower sales in Shave Care. Organic sales slid high single digits in Shave Care due to price reductions in the U.S. and negative product mix. Organic sales rose double digits in Appliances on increased volume from the continued success of innovation on Braun male styling and mid-tier shavers.

$PG {{ '2017-10-20T11:40:23+0000' | timeago}} • Announcement

$PG's beauty segment organic sales for 1Q18 increased 5% from a year ago. Organic sales were up double digits in Skin & Personal Care on growth in China, including the continued acceleration of the super-premium SK-II brand. Organic sales increased low single digits in Hair Care on increased pricing across regions behind product innovation.

$PG {{ '2017-10-20T11:40:11+0000' | timeago}} • Announcement

$PG reported a 5% rise in 1Q18 earnings on lower interest expense, higher interest income and a rise in non-operating income. Net income grew to $2.85Bil or $1.06 per share from $2.71Bil or $0.96 per share last year. Net sales rose 0.8% to $16.65Bil. Core EPS increased to $1.09 from $1.03. Organic sales rose 1% on higher shipment volume.

$ISRG {{ '2017-10-19T21:40:26+0000' | timeago}} • Announcement

Worldwide da Vinci procedures grew approx. 15% in 3Q17 as $ISRG shipped 169 da Vinci Surgical Systems during the quarter. With $TRXC already in its sight, Intuitive Surgical will also be eyeing $MDT with much more concern as Medtronic is set to roll out its surgical robot system next year.

$ISRG {{ '2017-10-19T21:22:14+0000' | timeago}} • Announcement

Amidst concern over an emerging competition for its da Vinci Surgical Systems, $ISRG posted its 3Q17 results where revenue increased 18% and profit grew 41%. Recently, the US FDA has shown the green light for $TRXC to market its Senhance Surgical Robotic System, the first system since 2010 to compete head-to-head against $ISRG's da Vinci system.

$GILD {{ '2017-10-19T16:10:20+0000' | timeago}} • Announcement

$GILD received approval from the US FDA for Yescarta, a new gene therapy developed by Kite Pharma for the treatment of adults with large B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed to respond to other treatments. Yescarta is a CAR-T therapy, which reprograms the body’s own immune cells to recognize and attack malignant cells.

$MYL {{ '2017-10-17T16:40:23+0000' | timeago}} • Announcement

$MYL announced that the United States District Court for the Eastern District of Texas issued a decision finding all asserted claims of the patents relating to Restasis invalid. The Court recognized that $AGN's patent protection for Restasis ended in 2014.

$GILD {{ '2017-10-17T16:06:03+0000' | timeago}} • Announcement

$GILD announced the promotion of Alessandro Riva, MD, to EVP, Oncology Therapeutics, with responsibility for the company’s hematology and oncology programs, including cell therapy research and development.

$AGN {{ '2017-10-16T21:26:34+0000' | timeago}} • Announcement

Drugmaker $AGN gets an adverse effect from the U.S. District Court for the Eastern District of Texas. The judge invalidated Allergan's Restasis patent deal, which was signed with the Mohawk Tribe in the last month. Allergan plans to appeal the ruling. Restasis, a dry-eye treatment drug,  generated $1.5Bil of revenues for Allergan in 2016.

$MDT {{ '2017-10-16T20:09:05+0000' | timeago}} • Announcement

$MDT said its Medtronic Care Management Services (MCMS) business and American Well entered into a strategic partnership. Under the agreement, the businesses will work together to enable patient access to American Well's telemedicine services on MCMS' video-enabled platforms, and to allow bi-directional data flow between the two parties.

Recent Transcripts

PG (The Procter & Gamble Company)
Friday, October 20 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
IMUC (ImmunoCellular Therapeutics, Ltd.)
Wednesday, August 23 2017 - 9:00pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
IONS (Ionis Pharmaceuticals, Inc.)
Tuesday, August 8 2017 - 3:30pm
ZTS (Zoetis Inc.)
Tuesday, August 8 2017 - 12:30pm
ARNA (Arena Pharmaceuticals Inc)
Monday, August 7 2017 - 8:30pm
IRWD (Ironwood Pharmaceuticals, Inc.)
Thursday, August 3 2017 - 8:30pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
ILMN (Illumina Inc.)
Tuesday, August 1 2017 - 8:30pm
AZN (AstraZeneca PLC)
Thursday, July 27 2017 - 12:30pm
ALKS (Alkermes plc)
Thursday, July 27 2017 - 12:30pm
PG (The Procter & Gamble Company)
Thursday, July 27 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm

AlphaGraphics you may like